AU2006289666A1 - Composition of whey growth factor extract for reducing muscle inflammation - Google Patents
Composition of whey growth factor extract for reducing muscle inflammation Download PDFInfo
- Publication number
- AU2006289666A1 AU2006289666A1 AU2006289666A AU2006289666A AU2006289666A1 AU 2006289666 A1 AU2006289666 A1 AU 2006289666A1 AU 2006289666 A AU2006289666 A AU 2006289666A AU 2006289666 A AU2006289666 A AU 2006289666A AU 2006289666 A1 AU2006289666 A1 AU 2006289666A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- whey
- growth factor
- factor extract
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
WO 2007/028211 PCT/AU2006/001323 COMPOSITION OF WHEY GROWTH FACTOR EXTRACT FOR REDUCING MUSCLE INFLAMMATION FIELD OF THE INVENTION The invention relates to the production of compositions containing milk products for use as a nutritional supplement. More specifically, it relates to 5 compositions containing whey growth factor extract, as well as their use in methods for reducing muscle inflammation in individuals undertaking resistance exercise training. BACKGROUND OF THE INVENTION The present invention is to be understood in light of what has previously 10 been done in the field. However, the following discussion is not an acknowledgement or admission that any of the material referred to was published, used or part of the common general knowledge in Australia as at the priority date of the application. The use of nutritional supplements by humans, and even animals, to 15 improve general health or to improve, for example, athletic performance, is known. Nutritional supplements are not intended to provide all the nutrients necessary for a complete diet, but instead are generally intended to complement the dietary intake such that it becomes more nutritionally complete. It is recognised that vitamins, minerals and other substances found in such 20 supplements play important physiological roles and that a deficiency of certain vitamins, minerals and/or other components of supplements has been linked to development of certain diseases, a decrease in general health or lower performance in athletes. Conversely, nutritional supplements are known to enhance a variety of 25 physiological states, under various conditions. There are many targets for nutritional supplements, for example sick patients, convalescing patients, elderly persons and persons undergoing strenuous exercise regimes who wish to improve their performance and/or recovery from such exercise. The nutritional requirements of bodybuilders and persons engaged in 30 strenuous physical exercise are quite particular, whether to decrease body fat and increase lean muscle mass, and or to improve recovery from the strenuous exercise. Recovery includes the ability to overcome exercise-induced inflammation.
WO 2007/028211 PCT/AU2006/001323 2 Inflammation is a localised response to injury or destruction of tissues. It is characterised in the acute form by pain, heat, redness, swelling, and loss of function. Accordingly, reduced muscle inflammation includes, but is not limited to a reduction in any one or more of the aforementioned symptoms in muscle. The 5 inflammatory response antagonises muscle protein synthesis and contributes to much of the physical discomfort experienced by persons 1 to 2 days after engaging in strenuous exercise, including resistance exercise training (Macintyre DL, et al., Sports Med. 1995; 20(1):24-40; MacIntyre DL, et al., Eur J Appl Physiol. 2001; 84(3):180-6). If the inflammation is severe, anti-inflammatory 10 drugs such as corticosteroids may be prescribed. However, the use of such drugs can have deleterious side-effects and, in many cases, is prohibited for athletes in competition. Weight-bearing or resistance training exercise elicits a wide-range of responses in the activated muscle. There are anabolic signalling pathways 15 activated by the stretch and strain of muscles and by growth factors which may be synthesised locally or circulate in the blood stream. Modulation of the expression of various genes is an essential process in regulating the sequence of cellular events needed to activate stem cells that are located within the muscle bed (satellite cells) (Anderson & Wozniak, Can J 20 Physiol Pharmacol. 2004; 82(5):300-10) to rapidly proliferate, before maturing and ultimately fusing with existing muscle fibres or joining together to create new muscle fibres. Regulators of the activation of satellite cells include Syndecan-3 (a transmembrane heparin sulphate proteoglycan essential for satellite cell proliferation), and Pax-7 (a protein that is essential for satellite cell activation and 25 necessary for muscle tissue repair) (Seale et al., Dev Biol. 2004; 275(2):287-300; Cornelison et al., Dev Biol. 2001; 239(1):79-94). Other genes involved in the exercise-induced muscle repair and inflammation process include the small molecular weight chemokines (CCL2 and CCL4) and the early response genes, jun-B and c-fos. 30 If a natural food product, such as a product derived from milk, could be obtained having beneficial effects on exercise recovery it would be a readily available and safe therapeutic supplement.
WO 2007/028211 PCT/AU2006/001323 3 It is known in the prior art to produce a milk product from cows maintained in a specific hyperimmune state, created by administering periodic booster immunisations with sufficiently high doses of antigens, which can be used to treat various diseases including arthritis, dermatitis and neoplastic diseases (EP 0 5 064103 Al, Beck LR). Normal cow's milk however does not contain the specific 'anti-inflammatory factor' present in milk produced from the aforementioned hyper-immunised animals, although it is believed to contain low levels of other anti-inflammatory factors. A person of skill in the art would appreciate that production of the anti-inflammatory milk products according to EP 0 064103 Al is 10 very expensive and time consuming. It is also known in the prior art to produce anti-inflammatory milk products comprising colostrum which is rich in immunoglobulins. Colostrum is the pre-milk produced immediately after birth before the breast secretions stabilize into milk. Prime colostrum from cows is obtained within the first six hours after calving and 15 contains four times the protein found in milk from the same cow obtained 48 hours later. The immunoglobulin fraction of colostrum is loaded with antibodies, lactoferrin and immune enhancers. Lactoferrin is thought to enhance the anti inflammatory effect of colostrum, and is the subject of US Patent 6,475,511 (Gohlke MB). Immunoglobulins are thought to act locally on immune function in 20 the gut. Protein supplementation has been used widely by persons undertaking resistance exercise training to promote muscle protein synthesis in order to repair muscle tissue and facilitate muscle growth. The nutritional supplementation may be provided in the form of a drink or food and includes protein powders to be 25 mixed with liquid for use, nutritional bars and snack foods, tablets, capsules and other preparations. Suitable protein sources commercially available include hydrolysed milk proteins, caseinates, soy protein isolates and milk protein concentrates prepared from ultra-filtrated skim milk. Nutritional supplements which are based on other protein sources, such as whey protein, are also 30 available and can be provided in the form of fruit juices, but are thought to be inadequate because they do not also provide a lipid source (WO 02/15720). In addition, it has been considered that some milk-derived proteins are not readily WO 2007/028211 PCT/AU2006/001323 4 absorbed by the gut, or do not survive the harsh environment of the digestive system to have a therapeutic effect. Whey growth factor extract (WGFE) is one such milk product which was thought to be susceptible to at least partial loss of biological activity once ingested 5 due to fragmentation of molecules such as growth factors. Moreover, by virtue of the process for its isolation, WGFE contains only low levels of immunoglobulins which, as described above, are thought to be important anti-inflammatory factors. Nevertheless, the capacity of whey protein supplementation to provide a benefit to persons engaged in resistance exercise training has been reported to 10 provide a benefit. Whey protein isolate (WPI) and milk protein isolate (MPI), each having a different composition to whey growth factor extract, have been reported to be effective with bodybuilders in rapidly gaining lean muscle mass while reducing body fat. WPI is high in branched-chain amino acids and considered to be fast-acting, whereas MPI is mainly casein which is more slowly metabolised 15 and is effective in promoting muscle growth. The use of WPI, or whey protein concentrate, in combination with the amino acids glutamine, leucine, isoleucine and valine to improve muscular fatigue in a rat model is the subject of WO 2004/049830 Al (Tsuchita H et al.). The authors measured Tyrosine release from soleus muscle as the indicator of fatigue. 20 The present inventors have found that a composition comprising whey growth factor extract altered the expression of genes involved in exercise-induced muscle inflammation. In a separate study conducted by the inventors, trained athletes administered whey growth factor extract reported a reduction in post exercise soreness. Importantly, in terms of the invention, whey growth factor 25 extract may be isolated from normal bulk milk products without a requirement to maintain cows in a hyperimmune state or to harvest colostrum which is in limited supply relative to other milk products. SUMMARY OF THE INVENTION The invention relates to a WGFE composition and method of using the 30 composition which enables persons undergoing resistance exercise training to reduce their level of muscle inflammation over that obtained with compositions of the prior art.
WO 2007/028211 PCT/AU2006/001323 5 It is thus an object of the present invention to provide a composition and method of using same which is improved/more efficacious than compositions of the prior art for reducing muscle inflammation. According to one aspect of the invention, there is provided a skeletal 5 muscle inflammation-reducing composition comprising whey growth factor extract, isolated from a milk product by cation exchange chromatography. In a further aspect of the invention, there is provided a muscle anti inflammatory composition comprising whey growth factor extract, isolated from a milk product by a process comprising the steps; 10 a) applying the milk product to a SP Sepharose cation exchange column, b) washing the column with a buffer of low ionic strength, c) eluting the WGFE fraction with a buffer containing in the range 0.4 0.5M NaCl, or equivalent ionic strength, at pH 6.5. 15 According to another aspect of the invention, there is provided a muscle anti-inflammatory composition comprising whey growth factor extract, isolated from a milk product by a process comprising the steps; a) applying the milk product to a SP Sepharose cation exchange column, 20 b) washing the column with a buffer of 0.008M NaCl or less, c) eluting the WGFE fraction with a buffer containing 0.4M NaCl, or equivalent ionic strength, at pH 6.5. In a further aspect of the invention, there is provided a composition according to the above wherein the whey growth factor extract is isolated from a 25 milk product selected from whole milk, cheese whey, rennet casein whey, acid casein whey, or concentrates thereof, or skim milk. In a further aspect of the invention, there is provided a composition according to the above when used as a muscle anti-inflammatory agent. In a further aspect of the invention there is provided a method of reducing 30 skeletal muscle inflammation in subjects undertaking resistance exercise training comprising administering to the subjects an efficacious amount of a composition comprising whey growth factor extract.
WO 2007/028211 PCT/AU2006/001323 6 In a further aspect of the invention there is provided a method of reducing skeletal muscle inflammation in subjects undertaking resistance exercise training comprising administering to the subjects an efficacious amount of a composition comprising whey growth factor extract, isolated from a milk product by a process 5 comprising the steps; a) applying the milk product to a SP Sepharose cation exchange. column, b) washing the column with a buffer of low ionic strength, c) eluting the WGFE fraction with a buffer containing in the range 0.4 10 0.5M NaCl, or equivalent ionic strength, at pH 6.5. In a further aspect of the invention there is provided a method of reducing skeletal muscle inflammation in subjects undertaking resistance exercise training comprising administering to the subjects an efficacious amount of a composition comprising whey growth factor extract, isolated from a milk product by a process 15 comprising the steps; a) applying the milk product to a SP Sepharose cation exchange column, b) washing the column with a buffer of 0.008M NaCl or less, c) eluting the WGFE fraction with a buffer containing 0.4M NaCl, or 20 equivalent ionic strength, at pH 6.5. In another aspect of the invention there is provided a method of reducing skeletal muscle inflammation in subjects undertaking resistance exercise training wherein the amount of whey growth factor extract administered, per daily dose, is at least 5mg/kg body weight to 12.5mg/kg body weight. Preferably the daily dose 25 of whey growth factor extract is at least 25mg/kg body weight. In a further aspect of the invention there is provided a use of whey growth factor extract, isolated from a milk product by cation exchange chromatography, for the production of a medicament for the treatment of a subject in need of reduced skeletal muscle inflammation. 30 In a further aspect of the invention there is provided a use of whey growth factor extract, isolated from a milk product by a process described above, for the production of a medicament for the treatment of a subject in need of reduced skeletal muscle inflammation.
WO 2007/028211 PCT/AU2006/001323 7 According to another aspect of the invention, there is provided a skeletal muscle inflammation-reducing composition comprising whey growth factor extract, isolated from a milk product by cation exchange chromatography, and an additional protein source. 5 According to a further aspect of the invention the additional protein source is whey protein, preferably whey protein isolate (WPI), more preferably whey protein isolate wherein the whey protein isolate comprises: Moisture 5.0% Fat 0.5% 10 pH (5% solution) 6.3 Ash 3.7% Lactose 0.5% Protein (TN x 6.38) 90.0% Sodium 0.7% 15 Phosphorous 0.3% Calcium 0.15% In a further aspect of the invention there is provided a method of reducing skeletal muscle inflammation in a subject undertaking resistance exercise training comprising administering to the subject an efficacious amount of a composition 20 comprising whey growth factor extract and an additional protein source, such as whey, preferably WPI. In a further aspect of the invention there is provided a method of reducing muscle inflammation in a subject undertaking resistance exercise training comprising administering to the subject a composition comprising an effective 25 amount of whey growth factor extract, isolated from a milk product by cation exchange chromatography, and an additional protein source taken separately. Preferably the amount of additional protein source administered, per daily dose, is at least 225mg/kg body weight (dry weight) and preferably at least 435mg/kg body weight (dry weight). 30 In a further aspect of the invention the administration of the composition of the invention is once per two or three days up to at least once per day, preferably before and/or immediately after resistance exercise training, more preferably WO 2007/028211 PCT/AU2006/001323 8 immediately after resistance exercise training, most preferably between 20 minutes and two hours after exercise. In a further aspect of the invention there is provided a use of whey growth factor extract, isolated from a milk product by cation exchange chromatography, 5 and an additional protein source for the production of a medicament for the treatment of a subject in need of reduced skeletal muscle inflammation. In a further aspect of the invention, there is provided a food or drink comprising the composition of the invention for use in a method to reduce skeletal muscle inflammation in a subject undertaking resistance exercise training. 10 In yet a further aspect of the invention there is provided a use of the composition of the invention for the manufacture of a food or drink to reduce skeletal muscle inflammation in a subject undertaking resistance exercise training. DESCRIPTION OF THE DRAWINGS 15 Figure 1: Fold change in Myo D, myogenin, and myostatin gene (mRNA) expression in the vastus lateralis muscle of adult subjects, at rest and following 3 hours of resistance exercise training performed at the start of the trial [pre training] and following 12 weeks of treatment [post-training] with 20g WPI (Group A), 1g WGFE + 20g WPI (Group B1), or 2g WGFE + 20g WPI (Group B2). 20 Results are presented as mean ± SEM. Figure 2: Fold change in Pax 7 and Syndecan 3 gene (mRNA) expression in the vastus lateralis muscle of adult subjects, at rest and following 3 hours of resistance exercise training performed at the start of the trial [pre-training] and following 12 weeks of treatment [post-training] with 20g WPI (Group A), 1g WGFE 25 + 20g WPI (Group B1), or 2g WGFE + 20g WPI (Group B2). Results are presented as mean ± SEM. Figure 3: Percentage of Pax 7 positive nuclei in tissue sections from the vastus lateralis muscle of adult subjects, following 3 hours of resistance exercise training performed at the start of the trial [pre-training] and following 12 weeks of 30 treatment [post-training] with 20g WPI (Group A), 1g WGFE + 20g WPI (Group B1), or 2g WGFE + 20g WPI (Group B2) as analysed by immunohistochemical staining.
WO 2007/028211 PCT/AU2006/001323 9 Figure 4: Fold change in IGF-1 Binding Protein 4 and 5 gene (mRNA) expression in the vastus lateralis muscle of adult subjects, at rest and following 3 hours of resistance exercise training performed at the start of the trial [pre training] and following 12 weeks of treatment [post-training] with 20g WPI (Group 5 A), 1g WGFE + 20g WPI (Group B1), or 2g WGFE + 20g WPI (Group B2). Results are presented as mean ± SEM. Figure 5: Fold change in Jun B and c-fos gene (mRNA) expression in the vastus lateralis muscle of adult subjects, at rest and following 3 hours of resistance exercise training performed at the start of the trial [pre-training] and 10 following 12 weeks of treatment [post-training] with 20g WPI (Group A), 1 g WGFE + 20g WPI (Group B1), or 2g WGFE + 20g WPI (Group B2). Results are presented as mean ± SEM. Figure 6: Fold change in CCL2, 4 and 7 gene (mRNA) expression in the vastus lateralis muscle of adult subjects, at rest and following 3 hours of 15 resistance exercise training performed at the start of the trial [pre-training] and following 12 weeks of treatment [post-training] with 20g WPI (Group A), 1 g WGFE + 20g WPI (Group B1), or 2g WGFE + 20g WPI (Group B2). Results are presented as mean ± SEM. Figure 7: TNF-alpha production (ng/ml) by RAW cells exposed to 20 lipopolysaccharide (LPS) and cultured in the presence of colostrum (sample 2BC), WPI (sample 4BC) at 100 mg/ml, WGFE (sample 6BC) at 100 mg/ml, various milk fractions, or LPS alone (control). WGFE and LPS were also added to the culture simultaneously (sample WGFE + LPS). The values plotted represent the arithmetic mean ±SEM of the average response obtained in 3 25 independent experiments. Figure 8: Comparison of TNF-alpha production (ng/ml) by RAW cells exposed to lipopolysaccharide (LPS) and cultured in the presence of 100 mg/ml WPI or 100 mg/ml WGFE. DETAILED DESCRIPTION OF THE INVENTION 30 The invention relates to a composition containing WGFE and uses thereof to enable a subject undergoing resistance exercise training to reduce their level of muscle inflammation over that obtained with compositions of the prior art.
WO 2007/028211 PCT/AU2006/001323 10 According to one aspect of the invention, there is provided a skeletal muscle inflammation-reducing composition comprising whey growth factor extract, isolated from a milk product by cation exchange chromatography. The whey growth factor extract for use in the invention may be isolated 5 from milk, skim milk, milk derivatives, whey, colostrum, and colostrum derivatives by, for example, the method described in Australian Patent No. 645589 (PCT/AU91/00303) which is incorporated herein by reference. This method essentially relies on strong cation exchange chromatography to selectively extract basic proteins from the starting material to constitute whey growth factor extract. 10 PROCESS FOR PRODUCING WGFE FRACTION A preferred method of producing WGFE for use in the invention is to use a column packed with SP (sulphopropyl) Sepharose To the column a flow of a dairy product, preferably skimmed milk, is applied until the volume of milk applied is up to 1000 times the volume of the resin packed into the column. The milk 15 remaining in the column is removed with a buffer of low ionic strength (<0.008M NaCI or equivalent) for 10 min. The WGFE fraction is eluted from the column with a buffer containing sodium ions equivalent to 0.4-0.5M NaCl (though other cations would be suitable), most preferably 0.4M NaCl. The mobile phase may have a pH within a broad range, such as 4.5-9.0, 20 preferably 5.5-7.5, most preferably about 6.5. At the upper and lower limits both protein stability and the ability of proteins to bind to the cation exchange resin become influenced. A pH in the range 5.5-7.5 provides the highest WGFE yields. The type of cation exchange resin suitable for adsorption of the WGFE components may include resins such as Sepharose cation exchange resin beads. 25 For example, SP Sepharose Big Beads and CM Sepharose beads (products of GE Healthcare) which contain sulfopropyl functional groups and carboxymethyl groups, respectively, are suitable. The size of the cation exchange resin beads is preferably in the range from 45-300pm. Both SP Sepharose beads in the range 45-165pm and in the range 100-300pm are suitable for WGFE purification 30 according to the invention. One of the further treatments to which the WGFE fraction can be subjected is desalting by, for example, dialysis or ultrafiltration.
WO 2007/028211 PCT/AU2006/001323 11 Accordingly, in a further aspect of the invention, there is provided a composition according to the above wherein the whey growth factor extract is isolated from whey or skim milk. The whey used as starting material may be cheese whey, rennet casein whey, acid casein whey, or concentrates thereof. 5 The amounts of whey growth factor extract and protein source to use according to the invention are to be sufficient for reduced muscle inflammation or to have a therapeutic effect. In another aspect of the invention there is provided a dosage regime wherein the amount of whey growth factor extract administered, per daily dose, is 10 at least 5mg/kg body weight to 12.5mg/kg body weight. Preferably the daily dose of whey growth factor extract is at least 25mg/kg body weight. In a further aspect of the invention there is provided a method of reducing skeletal muscle inflammation in subjects undertaking resistance exercise training comprising administering to the subjects an efficacious amount of a composition 15 comprising whey growth factor extract. When the composition includes an additional protein source, which may be any protein source suitable for consumption such as WPI, post-exercise inflammation is reduced compared to subjects administered a protein source alone. The protein source may be obtained from whole milk, preferably whey 20 protein and more preferably whey protein isolate (WPI). One such whey protein isolate is available commercially under the trade name NatraProTM by Murray Goulburn Co-Op Company Ltd. A typical composition of NatraProTM WPI includes: Moisture 5.0% 25 Fat 0.5% pH (5% solution) 6.3 Ash 3.7% Lactose 0.5% Protein (TN x 6.38) 90.0% 30 Sodium 0.7% Phosphorous 0.3% Calcium 0.15% WO 2007/028211 PCT/AU2006/001323 12 Preferably the composition according to the invention also contains a protein source and, in a dosage regime, the amount of additional protein source per daily dose administered is at least 225mg/kg body weight (dry weight) and preferably at least 435mg/kg body weight (dry weight). The additional protein 5 source could be formulated with the WGFE composition or formulated to be administered separately to the WGFE composition. In a further aspect of the invention there is provided a use of whey growth factor extract for the production of a medicament for the treatment of a subject in need of reduced skeletal muscle inflammation. For example, athletes may 10 require resistance exercise training to build up their muscle strength to enhance their performance, or to overcome a debilitating injury which has caused muscle wasting. The muscle inflammation may be caused by, for example, a 'corked' thigh, or a torn muscle. A medicament comprising the composition of the invention may further assist in the subject recovering more rapidly to return to 15 their training regime and/or to compete. Muscle inflammation may also occur in those with a propensity for bruising, such as the elderly. In a further aspect of the invention there is provided a method of reducing skeletal muscle inflammation in subjects undertaking resistance exercise training comprising administering to the subjects an efficacious amount of a composition 20 comprising whey growth factor extract and an additional protein source. It will be apparent to those skilled in the art that the administration of the composition of the invention may be on the days of training or on the days of training and/or other days, providing the regimen of administration results in reduced skeletal muscle inflammation. Preferably administration is on the days of 25 exercise and more preferably administration occurs either just before and/or immediately after the exercise. More preferably, administration occurs between 20 minutes and 2 hours after exercise. Accordingly, in a preferred aspect of the invention, there is provided a method as described above wherein the administration is immediately after the exercise. Subjects administered 1g WGFE 30 plus 20g WPI, or 2g WGFE plus 20g WPI immediately after resistance exercise training showed increased modulation of the expression of genes involved in inflammation compared to subjects administered WPI alone (see Examples and Results). In addition, subjects administered WGFE reported reduced post- WO 2007/028211 PCT/AU2006/001323 13 exercise soreness compared to those administered WPI, supporting a role for WGFE in reducing post-exercise muscle inflammation. Moreover, the composition of the invention may be used to reduce muscle inflammation in non-human mammals such as horses, greyhounds and others in 5 which reduced muscle inflammation is desirable. In a further aspect of the invention, there is provided a food or drink comprising the composition of the invention for use in a method to reduce skeletal muscle inflammation in subjects undertaking resistance exercise training. In yet a further aspect of the invention there is provided a use of the 10 composition of the invention for the manufacture of a food or drink to reduce skeletal muscle inflammation in subjects undertaking resistance exercise training. WPI typically contains about 90% w/v protein; therefore 20g of WPI contains about 18g of protein as a nutritional source. Whey growth factor extract typically contains about 85% w/v protein; 15 therefore 2g of whey growth factor extract contains about 1.7g of protein as a nutritional source. It will be appreciated that the present invention described herein is not to be limited to specific examples of features disclosed. EXAMPLES 20 Example 1: Clinical Trial A clinical trial was conducted in which 20 young males participated in a three month randomised double-blinded resistance training program. Whey growth factor extract was prepared according to the method broadly described in Australian Patent No. 645589 (PCT/AU91/00303), more specifically described 25 supra. Each whey protein formulation contained an artificial sweetener (NutrasweetTM, Nutrasweet Company, USA). Whey protein formulations were consumed immediately after each exercise session, with each subject completing three supervised exercise sessions per week. Subjects were randomly assigned to one of three supplement groups: 30 Group A: 20g NatraPro (WPI) per dose; n=7 Group B1: 20g NatraPro (WPI) plus 1g WGFE per dose; n=6 Group B2: 20g NatraPro (WPI) plus 2g WGFE per dose; n=7 WO 2007/028211 PCT/AU2006/001323 14 A typical composition of NatraProTM WPI includes: Moisture 5.0% Fat 0.5% pH (5% solution) 6.3 5 Ash 3.7% Lactose 0.5% Protein (TN x 6.38) 90.0% Sodium 0.7% Phosphorous 0.3% 10 Calcium 0.15% Muscle Analysis Muscle samples were collected from the vastus lateralis muscle of the right leg using the percutaneous needle biopsy technique. Excised muscle tissue was visually inspected, dissected free of any fat or connective tissue and blotted to 15 remove excess blood and immediately frozen in liquid nitrogen for subsequent analysis. A portion of the muscle tissue was mounted in an aqueous mounting medium and frozen in isopentane cooled in liquid nitrogen for subsequent immunohistochemical analysis. Immunohistochemistry 20 Serial sections (10pm) of each sample were mounted on microscope slides for analysis of myosin heavy chain fibre type. An immunohistochemical technique based on the fast and slow isoforms of myosin was used to examine fibre type distribution and muscle cross-sectional area based on the protocol of Behan. Cellular localisation of proteins was performed using standard 25 immunohistochemical techniques and antibodies raised against the proteins of interest. RNA extraction & gene expression analysis RNA was extracted from skeletal muscle samples using the ToTALLY RNA kit and reagents (Ambion Inc.) according to the manufacturer's instructions. Total 30 RNA concentrations and quality were determined using the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.). Subsequently, RNA was reverse WO 2007/028211 PCT/AU2006/001323 15 transcribed into cDNA using the AMV reverse transcriptase kit protocols and reagents (Promega). Analysis of gene expression was performed on the Applied Biosystems 7500 Real-Time PCR System using gene specific primers designed using Primer Express 2.0 software. 5 Protein expression analysis Standard western blotting techniques and an antibody directed towards a common section of myosin heavy chain protein isoforms (Zymed) was employed to examine total Myosin Heavy Chain protein content. RESULTS 10 Results are presented as mean ± SEM and significance calculated by two way ANOVA using Bonforoni post hoc tests. No significant differences in age, weight, height, or BMI values were observed both pre and post training. Table 1 - Subject Characteristics Subject NatraPro WPI (A) NatraPro WPI (B 1) NatraPro WPI (B 2) Characteristics (n=7) (r= 6) (n= 7 Age 20.4 0.6 19.5 ±0.6 19.0 0.4 Height 182.7 3.3 180 ± 5.2 182.3 i 4.1 Weight Pre Training 79.9 4.0 80.3 ± 4.6 79.3 6.0 Post 80.1 ± 3.2 80.0 i 4.7 80.9 i 5.9 Training BMI Pre Training 24.5 ± 0.8 24.3 1.0 23.9 1.1 Post 24.07 ± 1.1 24.2 1.0 24.4 1.0 Training 15 GENE EXPRESSION ANALYSIS There was no observed, consistent effect of training or treatments on the expression of MyoD and myogenin whilst training significantly increased the expression of muscle LIM protein (MLP) (Figure 1). The expression of Pax 7 and Syndecan 3, two markers of satellite cell recruitment and proliferation, was WO 2007/028211 PCT/AU2006/001323 16 increased 2-fold and 7-fold, respectively, following 12 weeks of training and is supported by protein expression data (Figures 2 and 3). The expression of IGFBP4 and IGFBP5 (Figure 4) were markedly increased in group BI at 12 weeks in response to acute exercise. The normal post-exercise up-regulation of 5 the early response genes jun-B and c-fos which are linked to muscle inflammation (Chen YW et al., J. App. Physiol. 2003; 95(6):2485-94) was attenuated in both B1 and B2 supplement groups suggesting a reduced stress response in these groups (Figure 5). At 12 weeks both the resting and post-exercise expression levels of CCL4 and CCL7 were increased following a single bout of resistance 10 exercise in groups B1 and B2 (significantly) compared with control group A (Figure 6). EXAMPLE 2: EFFECT OF WGFE ON LPS-INDUCED TNF-ALPHA EXPRESSION BY RAW CELLS. An in vitro study was conducted to test the effect of various milk product 15 fractions on LPS-induced pro-inflammatory TNF-alpha expression by RAW cells. RAW cells were grown in the presence of LPS and then colostrum (sample 2BC), WPI (sample 4BC) at 100 mg/ml, WGFE (sample 6BC) at 100 mg/ml, various milk fractions, was added. In one sample no milk product was added following LPS stimulation ('+ve' control). WGFE and LPS were also added to the culture 20 simultaneously (sample WGFE + LPS). The values plotted represent the arithmetic mean ±SEM of the average response obtained in 3 independent experiments (Figure 7). A comparison was done between the effect of WGFE and WPI on inhibition of LPS-induced TNF-alpha expression (Figure 8). Whey growth factor extract was prepared as for Example 1. 25 The data supports that WGFE reduces the inflammation response in muscle following resistance exercise training. In vitro data suggests that WGFE reduces inflammation by inhibiting TNF-alpha expression. The data also supports that WGFE in combination with an additional protein source such as WPI decreases the post-exercise inflammatory response to a greater extent than 30 observed when WPI, a protein source known to be used by subjects undertaking resistance exercise training, is administered alone.
Claims (21)
1. A muscle anti-inflammatory composition comprising whey growth factor extract, isolated from a milk product by cation exchange chromatography.
2. A muscle anti-inflammatory composition comprising whey growth factor 5 extract, isolated from a milk product by a process comprising the steps; a) applying the milk product to a SP Sepharose cation exchange column, b) washing the column with a buffer of low ionic strength, c) eluting the WGFE fraction with a buffer containing in the range 0.4 10 0.5M NaCl, or equivalent ionic strength, at pH 6.5.
3. A muscle anti-inflammatory composition comprising whey growth factor extract, isolated from skim milk by a process comprising the steps; a) applying the skim milk to a SP Sepharose cation exchange column, b) washing the column with a buffer of less than 0.008M NaCl, 15 c) eluting the WGFE fraction with a buffer containing 0.4M NaCl, at pH
6.5. 4. A muscle anti-inflammatory composition as claimed in any one of claims 1 to 3, further comprising an additional protein source. 5. The composition of claim 4 wherein the protein source is whey protein. 20 6. The composition of claim 5 wherein the whey protein is whey protein isolate (WPI).
7. The composition of claim 6 wherein the whey protein isolate comprises: Moisture 5.0% Fat 0.5% 25 pH (5% solution) 6.3 Ash 3.7% Lactose 0.5% WO 2007/028211 PCT/AU2006/001323 18 Protein (TN x 6.38) 90.0% Sodium 0.7% Phosphorous 0.3% Calcium 0.15% 5 8. The composition of any one of claims 1 to 7 wherein the whey growth factor extract is isolated from cheese whey, rennet casein whey, acid casein whey or skim milk.
9. The composition of claim 8 wherein the whey growth factor extract is isolated from skim milk. 10 10. A composition according to any one of claims 1 to 9 when used as a muscle anti-inflammatory agent.
11. A method of reducing muscle inflammation in a subject undertaking resistance exercise training comprising administering to the subject a composition comprising an effective amount of whey growth factor extract as described in any 15 one of claims 1 to 3.
12. The method of claim 11 wherein the composition is administered in a daily dose of at least 5mg/kg body weight to 12.5mg/kg body weight whey growth factor extract, preferably at least 25mg/kg body weight whey growth factor extract. 20 13. The method of claim 11 or 12 wherein the composition comprises an additional protein source.
14. A method of reducing muscle inflammation in a subject undertaking resistance exercise training comprising administering to the subject a composition comprising an effective amount of whey growth factor extract, isolated from a milk 25 product by cation exchange chromatography, and an additional protein source taken separately. WO 2007/028211 PCT/AU2006/001323 19
15. The method of claim 13 or 14 wherein the composition is administered in a daily dose of at least 5mg/kg body weight to 12.5mg/kg body weight whey growth factor extract, preferably at least 25mg/kg body weight whey growth factor extract, and at least 225mg/kg body weight of additional protein source. 5 16. The method of claim 15 wherein the additional protein source is as described in any one of claims 5 to 7.
17. The method of any one of claims 11 to 16 wherein the administration to the subject is once per two or three days up to at least once per day.
18. The method of any one of claims 11 to 16 wherein the administration to the 10 subject is before, and/or immediately after, resistance exercise training.
19. The method of any one of claims 11 to 16 wherein the administration is immediately after resistance exercise training.
20. The method of claim 18 wherein the administration is between 20 minutes and two hours after exercise. 15 21. Use of whey growth factor extract, isolated from a milk product by cation exchange chromatography, for the production of a medicament for the treatment of resistance exercise induced muscle inflammation.
22. Use of whey growth factor extract, isolated from a milk product by a process according to claim 2 or 3, for the production of a medicament for the 20 treatment of resistance exercise induced muscle inflammation.
23. Use of the composition of any one of claims (1 to 10) for the production of a medicament for the treatment of resistance exercise induced muscle inflammation.
24. A food, drink, tablet or capsule comprising the composition of any one of 25 claims (1 to 10) for use in a method according to any one of claims 11 to 20. WO 2007/028211 PCT/AU2006/001323 20
25. The food of claim 24, being in the form of a nutritional bar or snack food.
26. Use of the composition of any one of claims (1 to 10) for the manufacture of a food, drink, tablet or capsule to reduce muscle inflammation in a subject undertaking resistance exercise training. 5 27. A muscle anti-inflammatory composition, substantially as hereinbefore described with reference to the Examples.
28. Use of whey growth factor extract, substantially as hereinbefore described with reference to the Examples.
29. A method of reducing muscle inflammation in a subject undertaking 10 resistance exercise training, substantially as hereinbefore described with reference to the Examples.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006289666A AU2006289666B2 (en) | 2005-09-09 | 2006-09-08 | Composition of whey growth factor extract for reducing muscle inflammation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005904980 | 2005-09-09 | ||
AU2005904980A AU2005904980A0 (en) | 2005-09-09 | Compositions and method | |
PCT/AU2006/001323 WO2007028211A1 (en) | 2005-09-09 | 2006-09-08 | Composition of whey growth factor extract for reducing muscle inflammation |
AU2006289666A AU2006289666B2 (en) | 2005-09-09 | 2006-09-08 | Composition of whey growth factor extract for reducing muscle inflammation |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2006289666A1 true AU2006289666A1 (en) | 2007-03-15 |
AU2006289666B2 AU2006289666B2 (en) | 2012-09-20 |
Family
ID=39294203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006289666A Ceased AU2006289666B2 (en) | 2005-09-09 | 2006-09-08 | Composition of whey growth factor extract for reducing muscle inflammation |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2006289666B2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992000994A1 (en) * | 1990-07-13 | 1992-01-23 | Gropep Pty. Ltd. | Growth-promoting agent |
JPH05139990A (en) * | 1991-11-22 | 1993-06-08 | Snow Brand Milk Prod Co Ltd | Antiinflammatory agent containing secretory component as active ingredient |
NL1005677C2 (en) * | 1997-03-27 | 1998-09-29 | Campina Melkunie Bv | Method for recovering growth factors, or a composition containing one or more growth factors, from milk or a derivative thereof. |
US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
-
2006
- 2006-09-08 AU AU2006289666A patent/AU2006289666B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2006289666B2 (en) | 2012-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130078313A1 (en) | Milk derived composition and use to enhance muscle mass or muscle strength | |
US20190105371A1 (en) | Uses of casein compositions | |
JP4291513B2 (en) | Composition for improving physical work ability | |
JP2008512398A (en) | Human milk fortifier and its manufacturing method | |
JP2012530067A (en) | Glycomacropeptide medical food for nutritional management of phenylketonuria and other metabolic disorders | |
US9480717B2 (en) | Composition of whey growth factor extract for reducing muscle inflammation | |
KR100509681B1 (en) | Food composition for stimulating growth comprising fraction isolated from mammalian colostrum or milk whey | |
AU2013101214A4 (en) | Dairy product and process | |
AU2006289666B2 (en) | Composition of whey growth factor extract for reducing muscle inflammation | |
Gupta et al. | Whey proteins and its impact on human health nutrition: review | |
EP4307923A1 (en) | Liquid nutritional composition suitable for muscle function | |
JP2014201572A (en) | Muscle protein synthesis signal enhancer | |
AU2006289665B2 (en) | Milk derived composition and use to enhance muscle mass or muscle strength | |
Naclerio et al. | Effectiveness of whey protein supplement in resistance trained individuals | |
WO2014020678A1 (en) | Beverage, and method for producing same | |
Ahmadi-Vincu et al. | Colostrum as nutritional supplement in sport | |
Sergeevna et al. | Zinicheva Anastasiya Yur'evna, post graduate student |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
PC | Assignment registered |
Owner name: SAPUTO DAIRY AUSTRALIA PTY LIMITED Free format text: FORMER OWNER(S): MURRAY GOULBURN CO-OPERATIVE CO LIMITED |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |